摘要:
The present invention is directed to a method of screening for a carnitine transporter agonist or for a carnitine transporter antagonist, to a kit for carrying out the method of screening for a carnitine transporter agonist or for a carnitine transporter antagonist, to a method for the manufacture of a medicament for the treatment of a carnitine transporter deficiency, to methods of diagnosis of a carnitine transporter deficiency, to the use of a protein for the manufacture of an antibody reacting with a carnitine transporter, to an oligonucleotide and to methods of treatment of a carnitine transporter deficiency.
摘要:
The present invention refers to a test system for the identification of a ligand for angiotension receptor like-1 (APJ receptor) comprising an APJ receptor or a functional variant thereof and a Gαq or a Gαl protein or a hybrid protein which is assembled from portions of different G proteins like Gαq or Gαl proteins, a method of screening an APJ receptor ligand using the test system, a method for producing a medicament, a method for diagnosis and prognosis of a heart disease and a kit usable for detection or prognosis of a heart disease.
摘要:
The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.
摘要:
The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.
摘要:
The invention relates to substituted aminoindanes and analogs thereof of formula (I) and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders such as, for example, of respiratory disorders, cystic fibrosis disorders, acute or chronic renal disorders or bowel disorders.
摘要:
The present invention refers to a method for determining the activity of the organic cation transporter (OCT), a method for determining the activity of or identifying a chemical compound that modulates the activity of OCT with the help of a cell free electrophysiological sensor chip containing a solid-supported sensor electrode and a lipid layer containing the OCT located in the immediate spatial vicinity to the sensor electrode, whereas the sensor electrode is electrically insulated relative to the solutions used and to the lipid layer, as well as to the sensor chip itself and a kit containing same.
摘要:
The invention relates to substituted aminoindanes and analogs thereof of formula (I) and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders such as, for example, of respiratory disorders, cystic fibrosis disorders, acute or chronic renal disorders or bowel disorders.
摘要:
The present invention is directed to a method of screening for a carnitine transporter agonist or for a carnitine transporter antagonist, to a kit for carrying out the method of screening for a carnitine transporter agonist or for a carnitine transporter antagonist, to a method for the manufacture of a medicament for the treatment of a carnitine transporter deficiency, to methods of diagnosis of a carnitine transporter deficiency, to the use of a protein for the manufacture of an antibody reacting with a carnitine transporter, to an oligonucleotide and to methods of treatment of a carnitine transporter deficiency.